| IV Administration | SC Administration | |||||
---|---|---|---|---|---|---|---|
Number (%) of patients with | Placebo (n= 8) | 100 mg (n= 12) | 300 mg (n= 12) | All AMG 108 (n= 24) | Placebo (n= 88) | 75 mg (n= 12) | 300 mg (n= 94) |
Any adverse event | 8 (100) | 12 (100) | 12 (100) | 24 (100) | 74 (84) | 12 (100) | 77 (82) |
Most common AE | Â | Â | Â | Â | Â | Â | Â |
   Headache | 4 (50) | 9 (75) | 7 (58) | 16 (57) | 22 (25) | 4 (33) | 15 (16) |
   Upper respiratory tract infection | 1 (13) | 2 (17) | 5 (42) | 7 (29) | 7 (8) | 6 (50) | 9 (10) |
Infection | 3 (38) | 4 (33) | 8 (67) | 12 (50) | 18 (21) | 7 (58) | 25 (27) |
Injection-site reaction | 1 (13) | 1 (8) | 2 (17) | 3 (13) | 3 (3) | 0 | 7 (7) |
Treatment-related AE | 5 (63) | 8 (67) | 6 (50) | 14 (58) | 10 (11) | 0 | 28 (30) |
AE leading to study discontinuation | 0 | 0 | 0 | 0 | 1 (1) | 0 | 1 (1) |
Serious AE | 0 | 0 | 2 (17) | 2 (8) | 3 (3) | 0 | 2 (2) |
Treatment-related SAE | 0 | 0 | 1 (8) | 1 (4) | 0 | 0 | 1 (1) |
Serious infectious AE | 0 | 0 | 1 (8) | 1 (4) | 2 (2) | 0 | 1 (1) |
Death | 0 | 0 | 1 (8) | 1 (4) | 0 | 0 | 0 |